StockUS listing USSLNNASDAQHealthcareValue Trap

Silence Therapeutics PLC(SLN) Stock Analysis | Healthcare

USD --+0.00%
Reward41Moderate
Risk51Moderate
75%Data
Revenue growing 197% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.23Bn
Reward Ratingⓘ41 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ51 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SLN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Silence Therapeutics PLC?

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

AI Brief Pro

The brief on Silence Therapeutics PLC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Silence Therapeutics PLC?

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.23B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.344
Insider Activity
12M windowNo data
No insider activity data available for this ticker.